Dongcheng Pharmaceutical: Announcement on Subsidiary’s Application for Credit Line from Bank
Securities code: 002675 Securities abbreviation: Dongcheng Pharmaceutical Announcement number: 2025-074
Yantai Dongcheng Pharmaceutical Group Co., Ltd.
Announcement on Subsidiary's Application for Credit Line from Bank
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
In order to meet the needs of the company's rapid development and supplement the company's lack of liquidity, Yantai Dongcheng Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the 16th meeting of the company's sixth board of directors on December 15, 2025, and reviewed and approved the "Proposal on Subsidiaries' Application for Credit Lines from Banks". The subsidiaries applied for credit lines from various banks as follows:
Apply to Yantai Branch of China Everbright Bank Co., Ltd. for a credit line equivalent to RMB 200 million, with a credit period of no more than six years;
Apply to China CITIC Bank Co., Ltd. Yantai Branch for a credit line equivalent to RMB 200 million, with a credit period of no more than ten years;
Apply to China Minsheng Banking Co., Ltd. Hohhot Branch for a credit line equivalent to RMB 120 million, with a credit period of no more than five years;
The total credit limit applied by the subsidiary to the above-mentioned bank is RMB 520,000,000 (finally subject to the credit limit actually approved by the bank). The specific financing amount will be determined based on the actual needs of the company's operating funds, and will not exceed the above-mentioned specific credit amount; the financing term, interest rate, and type shall be subject to the signed contract. The company authorizes the chairman of the board of directors, Mr. Shouyi or his authorized representative, to sign on behalf of the company all contracts, agreements, vouchers and other legal documents related to all credit facilities (including but not limited to credit, loans, guarantees, mortgages, financing, trusts, leases, bank acceptance bills, domestic letters of credit, etc.) within the above credit limit. All legal and economic responsibilities arising therefrom shall be borne by the company.
The above credit line matters still need to be submitted to the company's third extraordinary shareholders' meeting in 2025 for review and approval. The authorization period starts from the date of approval of the company's third extraordinary shareholders' meeting in 2025 and ends on the date of the 2026 annual shareholders' meeting.
Announcement is hereby made.
Board of Directors of Yantai Dongcheng Pharmaceutical Group Co., Ltd.
December 16, 2025